$0.83
5.46%
Nasdaq, Nov 19, 04:00 pm EST. Closed.
ISIN
US84833T1034
Symbol
SPRO

Spero Therapeutics, Inc. Stock price

$0.83
-0.29 26.22% 1M
-1.76 68.10% 6M
-1.50 64.54% YTD
-1.55 65.28% 1Y
-0.40 32.82% 3Y
-15.67 94.99% 5Y
-10.67 92.81% 10Y
-10.67 92.81% 20Y
Nasdaq, Closing price Thu, Nov 19 2026
-0.05 5.46%
ISIN
US84833T1034
Symbol
SPRO
Industry

Is Spero Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,086 stocks worldwide.

Key metrics

Basic
Market capitalization
$48.1m
Enterprise Value
$-2.6m
Net debt
positive
Cash
$50.8m
Shares outstanding
58.2m
Valuation
P/E
6.9
P/S | estimate
1.0 | 169.2
EV/Sales | estimate
negative | negative
EV/FCF | ex SBC
negative | negative
P/B
1.1
Financial Health
Equity Ratio
85.6%
Return on Equity
14.5%
ROCE
14.9%
ROIC
-
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$4.0m | 8.5%
SBC as % of FCF
20.4%
SBC Growth 1Y
-32.7%
Share Count Growth 1Y
3.5%
Shareholder Yield
-3.5%
Financials
Revenue | estimate
$47.0m | $284.6k
EBITDA
-
EBIT
$6.6m
Net Income
$7.4m
Free Cash Flow | ex SBC
$19.6m | $15.6m
Growth
Revenue | estimate
-3.3% | -99.6%
EBITDA
-
EBIT
111.7%
Net Income
113.8%
Free Cash Flow
160.6%
Margin
Gross
-
EBITDA
-
EBIT
14.1%
Net
15.7%
Free Cash Flow | ex SBC
41.7% | 33.2%
More
EPS
$0.1
FCF per Share
$0.3
Short interest
1.6%
Employees
25
Rev per Employee
$2.7m

Spero Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Spero Therapeutics, Inc. forecast:

7x Buy
78%
2x Hold
22%

Analyst Opinions

9 Analysts have issued a Spero Therapeutics, Inc. forecast:

Buy
78%
Hold
22%

Spero Therapeutics, Inc. Events

Past Events
AUG
12
Q2 2026 Earnings Call
3 months ago

Financial data from Spero Therapeutics, Inc.

Jun '26
+/-
%
47 47
3% 3%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 20 20
20% 20%
42%
- Research and Development Expense 21 21
74% 74%
44%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 6.61 6.61
112% 112%
14%
Net Profit 7.38 7.38
114% 114%
16%

In millions USD.

Don't miss a Thing! We will send you all news about Spero Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Spero Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
●
8 days ago
SP001, an anti-CD40L antibody with potential across multiple immune-mediated diseases, advancing toward Phase 2 initiation in Immunoglobulin G4-related disease (IgG4-RD) Cash and cash equivalents of $107.9 million as of September 30, 2026, expected to fund operations into the second half of 2029 CAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clini...
Neutral
GlobeNewsWire
●
10 days ago
CAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines for patients with serious immune-mediated diseases, today announced the appointment of William Ho, M.D.
Neutral
GlobeNewsWire
●
16 days ago
CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immune-mediated diseases, today announced that the Compensation Committee of Spero's Board of Directors approved a grant, made on November 2, 2026, of an aggregate of 217,000 restricted stock unit awards (RSUs) ...
More Spero Therapeutics, Inc. News

Company Profile

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infections. Its pipeline product candidates include SPR994, SPR741, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.

Head office United States
CEO Ms. Rajavelu
Employees 25
Founded 2013
Website sperotherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today